The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France

NCT ID: NCT02618928

Last Updated: 2019-06-17

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

735 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-12-15

Study Completion Date

2018-03-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study seeks to determine the effectiveness of the interferon-free ABBVIE REGIMEN ± ribavirin (RBV) in participants with chronic hepatitis C (CHC) virus in clinical practices across France.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin

Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 8, 12, or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.

The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, and was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Treatment-naïve or -experienced participants with confirmed CHC, genotype 1 or 4
* Participants receiving or who will receive the interferon-free ABBVIE REGIMEN ± RBV according to product label
* RBV prescribed in line with the current local label

Exclusion Criteria

* Participant is not participating or intending to participate in a concurrent interventional therapeutic trial
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

AbbVie Inc.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hopital Saint Joseph /ID# 144927

Marseille, Bouches-du-Rhone, France

Site Status

Hopital Saint Joseph /ID# 145560

Marseille, Bouches-du-Rhone, France

Site Status

Hopital Saint Joseph /ID# 145571

Marseille, Bouches-du-Rhone, France

Site Status

CHR Orleans - Hopital de la Source /ID# 147250

Orléans, Centre-Val de Loire, France

Site Status

CHU de Besancon - Jean Minjoz /ID# 145884

Besançon, Doubs, France

Site Status

CHU Dupuytren /ID# 144920

Limoges, Franche-Comte, France

Site Status

Hopital Universitaire Purpan /ID# 145869

Toulouse, Haute-Garonne, France

Site Status

Hopital Universitaire Purpan /ID# 150141

Toulouse, Haute-Garonne, France

Site Status

Hopital Saint Eloi /ID# 144919

Montpellier, Herault, France

Site Status

Hopital de la Timone /ID# 145558

Marseille, Provence-Alpes-Côte d'Azur Region, France

Site Status

Hopital de la Timone /ID# 145574

Marseille, Provence-Alpes-Côte d'Azur Region, France

Site Status

CHU Amiens Picardie /ID# 145871

Amiens, Somme, France

Site Status

C.H. du Pays d'Aix /ID# 144922

Aix-en-Provence, , France

Site Status

Cabinet medical /ID# 147359

Aix-en-Provence, , France

Site Status

CHU d'Angers /ID# 145880

Angers, , France

Site Status

Centre Hospitalier Victor Dupo /ID# 147241

Argenteuil, , France

Site Status

Centre Hospitalier D'Avignon /ID# 151098

Avignon, , France

Site Status

Centre Hospitalier D'Avignon /ID# 151343

Avignon, , France

Site Status

Cabinet Medical /ID# 147322

Besançon, , France

Site Status

Centre Endo Nord Isere /ID# 148694

Bourgoin, , France

Site Status

Centre Hospitalier Universitai /ID# 147568

Caen, , France

Site Status

CH de Chambery /ID# 145573

Chambéry, , France

Site Status

Hopital Antoine Beclere /ID# 149251

Clamart, , France

Site Status

Hopital Antoine Beclere /ID# 149252

Clamart, , France

Site Status

Centre Hosp Intercommunal /ID# 145876

Créteil, , France

Site Status

Hospital Henri Mondor /ID# 144918

Créteil, , France

Site Status

Clinique du Palais /ID# 145563

Grasse, , France

Site Status

CHU de Grenoble - Albet Michal /ID# 145881

Grenoble, , France

Site Status

CH d'Hyeres /ID# 145870

Hyères, , France

Site Status

Ch Du Mans /Id# 147415

Le Mans, , France

Site Status

Dr. Cuissard, Le Port, FR /ID# 145565

Le Port, , France

Site Status

Centre Hospitalier de Libourne /ID# 145564

Libourne, , France

Site Status

CH Des Deux Vallees Longumeau /ID# 149336

Longjumeau, , France

Site Status

Hopital de la Croix Rousse /ID# 149776

Lyon, , France

Site Status

Ctr Consultations La Sauvegard /ID# 147236

Lyon, , France

Site Status

Hopital de la Timone /ID# 147237

Marseille, , France

Site Status

Ctre Hosp de Montelimar /ID# 147239

Montélimar, , France

Site Status

Cabinet Medical, Boyer Darrigr /ID# 145562

Nanterre, , France

Site Status

CHU de Nice /ID# 144921

Nice, , France

Site Status

Cabinet Medical, Dr. Verdier, /ID# 145575

Nîmes, , France

Site Status

Hopital Saint Antoine /ID# 145567

Paris, , France

Site Status

Hopital Saint Antoine /ID# 148635

Paris, , France

Site Status

Hopital Saint Antoine /ID# 148693

Paris, , France

Site Status

Hopital Saint Antoine /ID# 152825

Paris, , France

Site Status

Cabinet Medical, Giuily /ID# 145882

Paris, , France

Site Status

Hopital Bichat-Claude Bernard /ID# 149246

Paris, , France

Site Status

Cabinet Medical /ID# 145559

Paris, , France

Site Status

Hopital Pitie Salpetriere /ID# 145556

Paris, , France

Site Status

Hopital Pitie Salpetriere /ID# 145566

Paris, , France

Site Status

Hopital Pitie Salpetriere /ID# 149337

Paris, , France

Site Status

Hopital Bichat Claude Bernard /ID# 145886

Paris, , France

Site Status

Hopital Tenon /ID# 145885

Paris, , France

Site Status

CH Marechal Joffre /ID# 145875

Perpignan, , France

Site Status

CHU Jean Bernard /ID# 147414

Poitiers, , France

Site Status

CHU de Reims /ID# 148477

Reims, , France

Site Status

Hospital Pontchaillou /ID# 145883

Rennes, , France

Site Status

Charles Nicolle Hosp chu rouen /ID# 145557

Rouen, , France

Site Status

Institut Arnault Tzanck /ID# 144925

Saint-Laurent-du-Var, , France

Site Status

Hopital Begin /ID# 145872

Saint-Mandé, , France

Site Status

CHU Strasbourg Hautepierre Hos /ID# 147246

Strasbourg, , France

Site Status

Hopital Foch /ID# 147248

Suresnes, , France

Site Status

Cabinet Medical, Dr. Constant, /ID# 145561

Toulon, , France

Site Status

Clinique Amroise Pare /ID# 144924

Toulouse, , France

Site Status

Hopital Joseph Ducuing /ID# 152832

Toulouse, , France

Site Status

Ctre Hospitalier de Tourcoing /ID# 145568

Tourcoing, , France

Site Status

Cabinet Medical, Barbereau /ID# 145874

Tours, , France

Site Status

Hopital Paul Brousse /ID# 145879

Villejuif, , France

Site Status

Hopital Paul Brousse /ID# 147244

Villejuif, , France

Site Status

Hopital Paul Brousse /ID# 147417

Villejuif, , France

Site Status

Hopital Beaujon /ID# 147923

Clichy, Île-de-France Region, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Ferenci P, Bourgeois S, Buggisch P, Norris S, Curescu M, Larrey D, Marra F, Kleine H, Dorr P, Charafeddine M, Crown E, Bondin M, Back D, Flisiak R. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. J Viral Hepat. 2019 Jun;26(6):685-696. doi: 10.1111/jvh.13080. Epub 2019 Mar 5.

Reference Type DERIVED
PMID: 30739368 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P15-405

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.